July 16 (Reuters) - Sarepta Therapeutics ( SRPT ) said
on Wednesday it would lay off 36% of its workforce, or about 500
employees.
The workforce reduction comes shortly after the company
reported two deaths due to acute liver failure in non-ambulatory
Duchenne muscular dystrophy patients who had received its gene
therapy, Elevidys.